摘要
目的探讨核苷酸切除修复交叉互补基因1(ERCC1),乳腺癌易感基因1(BRCA1)的表达与原发性上皮性卵巢癌患者临床病理特征及铂类化疗敏感性的关系,以评价ERCC1和BRCA1基因对原发性上皮性卵巢癌铂类化疗敏感性的预测价值。方法收集48例接受卵巢癌分期手术及满意或较满意的肿瘤细胞减灭术的原发性上皮性卵巢癌患者肿瘤标本,采用免疫组化方法检测ERCC1及BRCA1的表达,并分析ERCC1及BRCA1基因表达与卵巢上皮性癌临床病理特征、临床化疗疗效的关系。结果 ERCC1的表达与原发性卵巢上皮性癌患者的临床分期有关(P<0.05),与年龄、病理类型、分化程度均无关(P>0.05),BRCA1的表达与原发性卵巢上皮性癌患者年龄、病理类型、分化程度及临床分期均无关(P>0.05);耐药者ERCC1高表达率高于敏感者,差异有统计学意义(P<0.05),耐药者BRCA1高表达率高于敏感者,但差异无统计学意义(P>0.05);ERCC1在卵巢上皮性癌中阳性表达率为89.58%,BRCA1在卵巢上皮性癌中阳性表达率为25.00%。结论 ERCC1的表达与原发性卵巢上皮性癌患者的临床分期有关,与年龄、病理类型、分化程度均无关,BRCA1的表达与原发性卵巢上皮癌患者的临床病理特征无关;ERCC1在卵巢上皮性癌中的阳性表达率高,与临床含铂类化疗方案的敏感性有关;BRCA1在卵巢上皮性癌中的阳性表达率低。
Objective To investigate the association of ERCC1 and BRCA1 gene expression with clinical features and sensitivity to platinum-containing chemotherapy in patients with ovarian epithelial carcinoma. Methods Primary ovarian epithelial carcinoma tissues were harvested from 48 patients receiving staging surgery or cytoreductive surgery. Expression of ERCC1 and BRCA1 in the tumor samples was detected by immunohistoehemistry. Results ERCC1 expression was correlated with clinical stage （P〈0.05） but not with age, pathological type or degree of differentiation （P〉0.05）. BRCA1 expression was not correlated with any of the clinicopathological features （P〉0.05） ;ERCC1 expression was significantly higher in drug-resistant tissues than in drug-sensitive samples （ P〈0.05 ） ;The expression of ERCC1 and BRCA1 was positive in 89.58% and 25.00% of the samples, respectively. Conclusion ERCC1 gene expression is correlated with clinical stage but not with age, pathological type or degree of differentiation. BRCA1 gene expression is not correlated with elinieopathological features. ERCC1 has high positive expression in epithelial ovarian cancer and is correlated with sensitivity of platinum-containing adjuvant chemotherapy.
出处
《医药导报》
CAS
北大核心
2014年第6期747-751,共5页
Herald of Medicine
基金
广东省医学科学技术研究基金资助项目(A2013257)
